The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: A systematic review and Meta-analysis

Han, Ying; Zeng, Ajuan; Liao, Huiyu; Liu, Yanmin; Chen, Yuhan; Ding, Huiguo

doi:10.1016/j.intimp.2016.11.022

Cited by 69 publications

(65 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, studies using sensitive markers of glomerular and tubular kidney function and of bone mineral density have also reported chronic tubular damage and decline of eGFR and bone mineral density in TDF treated patients. 70,[79][80][81][82][83][84][85][86][87] Therefore, it seems appropriate for now to monitor all CHB patients treated with TDF therapy for adverse renal effects with serum creatinine (eGFR) and serum phosphate levels. Moreover, CHB patients at high renal risk undergoing any NA therapy should be monitored with serum creatinine (eGFR) levels.…”

Section: Monitoring Of Patients Treated With Etv Tdf or Taf Recommenmentioning

confidence: 99%

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

Lampertico¹,

Agarwal²,

Berg³

et al. 2017

Journal of Hepatology

4,032

3,081

View full text Add to dashboard Cite

Section: Monitoring Of Patients Treated With Etv Tdf or Taf Recommenmentioning

confidence: 99%

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

Lampertico¹,

Agarwal²,

Berg³

et al. 2017

Journal of Hepatology

4,032

3,081

View full text Add to dashboard Cite

“…However, in previous trials of TDF and ETV, the baseline renal conditions and risk factors were not analysed in detail, with the exception of normal mean eGFR. Moreover, the results of renal safety profiles from several observational studies compared TDF and ETV in CHB patients, in which various definitions and cutoff values were used, remained conflicting . Of importance is that the baseline conditions which are strongly related to chronic kidney disease (CKD), including the CKD stage, proteinuria, and haematuria, have not been completely analysed.…”

Section: Introductionmentioning

confidence: 99%

Using the chronic kidney disease guidelines to evaluate the renal safety of tenofovir disoproxil fumarate in hepatitis B patients

Tsai

Chuang

Lee

et al. 2018

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…While HP NAs with good renal safety pro le are preferred since most of the patients require lifelong treatment. Minimal rates of renal function decline had been reported during long-term therapy with ETV and TDF in patients with CHB, while the nephrotoxic potential was higher for TDF 20,[72][73][74] . There had been several cases about TDF-associated Fanconi syndrome, including one LT recipient [75][76][77] .…”

Section: Discussionmentioning

confidence: 95%

The Strategy and Efficacy of Prophylaxis Against Hepatitis B Virus Recurrence After Liver Transplantation in the Era of High Potent Nucleos(t)ide Analogues: A Meta-Analysis

Li¹,

Hou²,

Yao³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: High potent nucleos(t)ide analogues (HP NAs) with or without hepatitis B immunoglobulin (HBIG) is the standard prophylactic therapy for avoiding the HBV recurrence after liver transplantation (LT). While the clinical impact of HP NAs-based prophylaxis has not been well documented, the optimal treatment strategy is currently debated. This meta-analysis aims to evaluate clinical outcome of LT recipients under HP NAs-based regimens and investigate different prophylaxis schemes. Methods: We followed PRISMA statement to conduct this study. Two reviewers independently searched relevant literature via PubMed, EMBAES, MEDLINE, Web of Science, and Google Scholar. Studies were included if they observed HBV recurrence under HP NAs-based regimens in patients who received HBV-related LT. Primary and secondary outcome were HBV recurrence, HCC recurrence, all-cause and HBV-recurrence related mortality. Incidence with 95% confidence intervals was aggregated and assess by fixed effect model/random effect model. Subgroup analysis was applied to examine the impact of different treatment strategies. Results: 26 studies (n=2374) were included, with a pooled HBV recurrence rate of 0.92% (95% CI 0.47%-1.48%). Studies with and without HBV viremia or HDV superinfected patients demonstrated comparable HBV recurrence (p=0.25, p=0.69). Recurrence rate under indefinite combination of HP NAs and HBIG was lower than that under HP NAs monotherapy (p=0.0003), and similar to that under NAs plus finite course of HBIG (p=0.53). Pooled HCC recurrence rate was 5.34% (95% CI 0.78%-12.48%). HBV-recurrence related mortality and all-cause mortality were 0.17% (95% CI 0.00%-1.51%) and 7.29% (95% CI 4.42%–10.71%) respectively. Conclusion: Our study suggests HP NAs-based regimens provide satisfactory HBV antiviral prophylaxis and improved long-term outcome for LT recipients. Finite combination of HP NAs and HBIG is an alternative to lifelong dual therapy.

show abstract

The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: A systematic review and Meta-analysis

Cited by 69 publications

References 35 publications

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

Using the chronic kidney disease guidelines to evaluate the renal safety of tenofovir disoproxil fumarate in hepatitis B patients

The Strategy and Efficacy of Prophylaxis Against Hepatitis B Virus Recurrence After Liver Transplantation in the Era of High Potent Nucleos(t)ide Analogues: A Meta-Analysis

Contact Info

Product

Resources

About